Project Grant R21AG099223
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $451K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Albany, NY 12208, USA
Similar Awards
- The National Institute on Aging awarded the Regenerative Research Foundation $428,175 on February 15, 2026, under the Aging Research program (CFDA 93.866) to develop a human induced pluripotent stem cell (iPSC)-derived three-dimensional vascular microphysiological model for studying cerebral amyloid angiopathy and Alzheimer's disease-related vascular pathology. The recipient will establish a 3D model incorporating microglia and vascular endothelial cells within a microfluidic device to enable...
- The National Institute on Aging awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $357,000 under the Aging Research program (CFDA 93.866) on September 1, 2026, to investigate endothelial pannexin1-induced inflammation in Alzheimer's disease. The research tests the hypothesis that amyloid-beta upregulates cerebral endothelial pannexin1 expression, which promotes vascular dysfunction and Alzheimer's disease progression through increased neuroinflammation and...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded Albany Medical College $1.951689 million on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds investigation of inflammation-resolution pathways to address vascular contributions to cognitive impairment and dementia (VCID) in the context of atherosclerosis....
- The National Institute on Aging awarded Rensselaer Polytechnic Institute $698,712 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate apolipoprotein E and reelin interactions in Alzheimer's disease pathology. The research tests the hypothesis that APOE E4 competes with reelin for receptor and heparan sulfate binding, thereby reducing protective reelin signaling and increasing Alzheimer's disease risk. Work includes mechanistic studies using split luciferase assays...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $704,145 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and apply computational methods for inferring the natural history of Alzheimer's disease from sparse longitudinal molecular and neuroimaging data. The recipient will develop an innovative approach that leverages temporal signal in sparse longitudinal datasets to reconstruct the timeline of Alzheimer's disease progression and...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $230,388 on March 4, 2026, under the Aging Research program (CFDA 93.866) to dissect the role of the PICALM/EED locus on myeloid cells in Alzheimer's disease. The recipient will conduct research to understand how an Alzheimer's disease risk enhancer on chromosome 11 influences expression of two target genes—PICALM (phosphatidylinositol binding clathrin assembly protein) and EED (embryonic ectoderm development)—and to...
- The National Institute on Aging awarded the University of California, San Diego $674,455 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of vascular sphingolipid metabolism in Alzheimer's disease. The research examines how cerebral blood vessels change in Alzheimer's disease patients through mass spectrometry-based proteomics and lipidomics analysis. Prior work identified downregulation of lipid metabolic enzymes and altered lipid composition in brain...
- The National Institute on Aging awarded the University of Wisconsin-Madison $427,625 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate cerebral small vessel disease pathways in vascular contributions to cognitive impairment and dementia and Alzheimer's disease using ferumoxytol-enhanced MRI. The research will employ novel microvascular biomarkers including quantitative characterization of vascular density and hemodynamic measures of microvascular pulsatility...
- The National Institute on Aging awarded New York University $712,578 on February 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a prospective study identifying viral infections associated with cognition decline and Alzheimer's disease risk across three prospective cohorts. The award supports comprehensive serologic profiling using VirScan, a bacteriophage immunoprecipitation sequencing technology, to detect immune responses to human viruses and analyze antiviral antibodies in...